RecruitingNCT04114994

Longitudinal Cognitive Assessment by BoCA

Sponsor

Alzheimer's Light LLC

Enrollment

10,000 participants

Start Date

Oct 1, 2019

Study Type

OBSERVATIONAL

Conditions

Multiple Sclerosis Alzheimer Disease Parkinson Disease Mild Cognitive Impairment Frontotemporal Dementia Vascular Dementia TBI

Summary

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking changes in thinking and memory over time in older adults using a test called the BoCA (Brief Online Cognitive Assessment). The goal is to better understand how cognition changes as people age and to validate this assessment tool. **You may be eligible if...** - You are 50 years of age or older **You may NOT be eligible if...** - You are younger than 50 years old Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBoston Cognitive Assessment (BoCA)

The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals. BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance. After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts.

Locations(1)

Andrey Vyshedskiy

Miami, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04114994

Related Trials

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT0684732135 locations

Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?

NCT053577811 location

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

NCT000012481 location

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

NCT027842101 location